head and neck cancer

Adlai Nortye IPO gives old Novartis cancer drug new life
Adlai Nortye IPO gives old Novartis cancer drug new life
BioPharma Dive
Adlai Nortye
IPOs
Novartis
AN2025
head and neck cancer
solid tumors
Flag link:
Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer
Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer
BioSpace
Merck
Eisai
Keytruda
Lenvima
clinical trials
head and neck cancer
Flag link:
Alentis’ ALE.C04 receives fast track designation from FDA
Alentis’ ALE.C04 receives fast track designation from FDA
Pharmaceutical Business Review
Alentis Therapeutics
FDA
ALE.C04
metastatic head and neck squamous cell carcinoma
head and neck cancer
Flag link:
Galera Lays Off 70% of Staff After FDA Rejection in Severe Oral Mucositis
Galera Lays Off 70% of Staff After FDA Rejection in Severe Oral Mucositis
BioSpace
Galera Therapeutics
avasopasem manganese
layoffs
oral mucositis
head and neck cancer
FDA
Flag link:
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
FDA
graft vs host disease
head and neck cancer
postpartum depression
major depressive disorder
Mesoblast
remestemcel-L
Biogen
SAGE Therapeutics
zuranolone
Galera Therapeutics
avasopasem manganese
Flag link:
CEL-SCI's multi-decade Multikine journey extends with FDA request for new trial
CEL-SCI's multi-decade Multikine journey extends with FDA request for new trial
Fierce Biotech
Cel-Sci
Multikine
head and neck cancer
FDA
clinical trials
Flag link:
J&J Extends Lifeline to Nanobiotix in Potential $1.8B Licensing Deal
J&J Extends Lifeline to Nanobiotix in Potential $1.8B Licensing Deal
BioSpace
JNJ
Nanobiotix
NBTXR3
radiotherapy
head and neck cancer
Flag link:
Eisai goes after head and neck cancer in Made of More campaign
Eisai goes after head and neck cancer in Made of More campaign
Medical Marketing and Media
Eisai
head and neck cancer
pharma marketing
Flag link:
ASCO 2023 – Bicara eyes head and neck niche
ASCO 2023 – Bicara eyes head and neck niche
EP Vantage
ASCO 2023
Bicara Therapeutics
BCA101
head and neck cancer
Flag link:
Eyeing untapped niche, EpicentRx makes case for cancer toxicity prevention drug
Eyeing untapped niche, EpicentRx makes case for cancer toxicity prevention drug
Fierce Biotech
EpicentRx
clinical trials
head and neck cancer
oral mucositis
RRx-001
Flag link:
Cue's IL-2-based Biologic Shows Early Promise in Head and Neck Cancer
Cue's IL-2-based Biologic Shows Early Promise in Head and Neck Cancer
BioSpace
Cue Biopharma
CUE-101
head and neck cancer
Flag link:
ESMO: Merck's Keytruda chalks up failure in head and neck cancer. But experts see silver lining
ESMO: Merck's Keytruda chalks up failure in head and neck cancer. But experts see silver lining
Fierce Pharma
Merck
Keytruda
head and neck cancer
ESMO
Flag link:
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Yahoo Finance
ESMO
Adaptimmune
clinical trials
ADP-A2M4CD8
ovarian cancer
head and neck cancer
urothelial cancer
Flag link:
Merck’s Keytruda fails head and neck cancer trial
Merck’s Keytruda fails head and neck cancer trial
CNBC
Merck
Keytruda
head and neck cancer
clinical trials
Flag link:
Galera's stock plunges 73% on disappointing test results for lead cancer drug candidate
Galera's stock plunges 73% on disappointing test results for lead cancer drug candidate
Bizjournals
Galera Therapeutics
cancer
clinical trials
head and neck cancer
oral mucositis
GC4419
Flag link:
Bristol Myers Squibb takes another late-stage loss for Opdivo-Yervoy combo in head and neck cancer
Bristol Myers Squibb takes another late-stage loss for Opdivo-Yervoy combo in head and neck cancer
Endpoints
Bristol Myers Squibb
Opdivo
head and neck cancer
clinical trials
Flag link:
Cel-Sci's 11-year cancer drug odyssey ends in failure, sinking stock, but plots FDA filing anyway
Cel-Sci's 11-year cancer drug odyssey ends in failure, sinking stock, but plots FDA filing anyway
Fierce Biotech
Cel-Sci
immunotherapy
clinical trials
head and neck cancer
Multikine
Flag link:
AstraZeneca's Imfinzi Fails To Prolong Survival In Late-Stage Head And Neck Cancer Study
AstraZeneca's Imfinzi Fails To Prolong Survival In Late-Stage Head And Neck Cancer Study
Benzinga
AstraZeneca
head and neck cancer
Imfinzi
clinical trials
Flag link:
ALX Oncology Pairs Lead Asset with Keytruda in HNSCC Study
ALX Oncology Pairs Lead Asset with Keytruda in HNSCC Study
BioSpace
ALX Oncology
Merck
head and neck cancer
ALX148
Keytruda
Flag link:
ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial
ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial
Fierce Pharma
ESMO
Pfizer
Merck KGaA
Bavencio
head and neck cancer
clinical trials
Flag link:

Pages